Copyright
©The Author(s) 2025.
World J Psychiatry. Jun 19, 2025; 15(6): 105409
Published online Jun 19, 2025. doi: 10.5498/wjp.v15.i6.105409
Published online Jun 19, 2025. doi: 10.5498/wjp.v15.i6.105409
Table 2 Key findings on the effects based on the positive and negative syndrome scale scores from completed 5-week clinical trials
Variable | EMERGENT-1[43] | EMERGENT-2[14] | EMERGENT-3[47] | |||
KarXT vs placebo | P value | KarXT vs placebo | P value | KarXT vs placebo | P value | |
Number of patients (modified intention-to-treat population) | 83 vs 87 | - | 117 vs 119 | - | 114 vs 120 | - |
Least-squares mean change from baseline in PANSS total score (points) | -17.4 vs -5.9 | < 0.001 | -21.2 vs -11.6 | < 0.0001 | -20.6 vs -12.2 | < 0.0001 |
Least-squares mean change from baseline in PANSS positive symptom subscore (points) | -5.6 vs -2.4 | < 0.001 | -6.8 vs -3.9 | < 0.0001 | -7.1 vs -3.6 | < 0.0001 |
Least-squares mean change from baseline in PANSS negative symptom subscore (points) | -3.2 vs -0.9 | < 0.001 | -3.4 vs -1.6 | 0.0055 | -2.7 vs -1.8 | 0.1224 |
Least-squares mean change from baseline in PANSS Marder negative symptom subscore (points) | -3.9 vs -1.3 | < 0.001 | -4.2 vs -2.0 | 0.0022 | -3.5 vs -2.7 | 0.1957 |
- Citation: Pejčić AV. Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride. World J Psychiatry 2025; 15(6): 105409
- URL: https://www.wjgnet.com/2220-3206/full/v15/i6/105409.htm
- DOI: https://dx.doi.org/10.5498/wjp.v15.i6.105409